Low Testosterone

← Back to Conditions

Category: Hormonal Health  |  Also addressed: Hypogonadism, Testosterone Deficiency Syndrome, Andropause

What Is Low Testosterone?

Low testosterone, clinically termed hypogonadism or testosterone deficiency syndrome, is a condition in which the body does not produce adequate testosterone to support normal physiological function. Testosterone is not simply a sex hormone. It is an anabolic, metabolic, and neurological hormone with receptors in skeletal muscle, bone, brain, cardiovascular tissue, liver, and adipose tissue. When levels fall below the range required for optimal function, the consequences extend across virtually every system in the body.

The challenge in conventional medicine is that "low testosterone" is defined by a laboratory threshold that does not account for individual variation in symptom burden. A man with a total testosterone of 320 ng/dL may be told his levels are "borderline normal" while experiencing debilitating fatigue, loss of muscle despite consistent training, declining cognitive sharpness, and diminished sexual function. In functional medicine, the goal is not to treat a number but to restore the hormonal environment in which the patient actually feels and functions optimally.

Why It Matters

Testosterone deficiency is not a condition that affects only sexual function and gym performance. Its systemic consequences are clinically significant across cardiovascular, metabolic, musculoskeletal, neurological, and psychological domains. Understanding this scope is essential for recognizing how frequently low testosterone is the unaddressed driver behind symptoms that are attributed to aging, stress, or other causes.

Common Symptoms

The symptom profile of low testosterone is broad and nonspecific, which is why it is so frequently attributed to aging, stress, or overwork rather than investigated as a hormonal condition. When multiple symptoms from the clusters below are present simultaneously in a man over 30, testosterone evaluation is warranted regardless of age.

Root Causes: A Functional Medicine Perspective

Before initiating testosterone replacement, identifying the mechanism driving the deficiency guides both the treatment decision and the approach. Primary and secondary hypogonadism have different causes, different treatment implications, and different reversibility profiles.

Metabolic

Insulin resistance and obesity are the most common and most reversible metabolic drivers of low testosterone. Visceral adiposity increases aromatase activity, converting testosterone to estradiol in adipose tissue and lowering the net testosterone pool. Hyperinsulinemia directly impairs Leydig cell testosterone synthesis through insulin receptor-mediated signaling that disrupts the steroidogenic enzyme cascade. Restoring insulin sensitivity through weight management, resistance training, and dietary intervention raises endogenous testosterone in a meaningful proportion of men with metabolic-driven hypogonadism, sometimes without requiring exogenous testosterone at all.

Hormonal

The pituitary-testicular axis is regulated by LH from the pituitary, which drives Leydig cell testosterone production. Any factor that suppresses LH, including elevated prolactin (from a pituitary adenoma), elevated estradiol (from aromatization), exogenous anabolic steroid or testosterone use (which suppresses the axis through negative feedback), and opioid use (which suppresses hypothalamic GnRH pulsatility), will produce secondary hypogonadism with low testosterone and inappropriately low or normal LH. Cortisol excess from chronic stress or HPA axis dysregulation suppresses GnRH pulsatility through a direct hypothalamic mechanism, reducing the LH drive to the testes.

Inflammation

Chronic systemic inflammation directly impairs Leydig cell steroidogenic enzyme function through inflammatory cytokine signaling (IL-1 beta, TNF-alpha, IL-6) that downregulates CYP17A1 and other steroidogenic enzymes required for testosterone biosynthesis. Men with elevated hs-CRP or other inflammatory markers frequently have lower testosterone than expected for their age, and anti-inflammatory interventions produce measurable testosterone improvement in this subgroup. The relationship is bidirectional: low testosterone itself increases inflammatory cytokine production, creating a hormonal-inflammatory feedback cycle.

Gut

The gut microbiome contributes to testosterone regulation through multiple pathways. Certain gut bacteria express beta-glucuronidase, an enzyme that deconjugates steroid hormones in the intestine and influences their enterohepatic recirculation. Dysbiosis alters the gut-liver axis in ways that affect SHBG production, estrogen clearance, and the inflammatory burden that impairs Leydig cell function. Gut permeability with LPS translocation activates systemic inflammatory pathways that suppress testosterone synthesis through the same cytokine-mediated mechanism as direct inflammation.

Nutritional and Environmental

Zinc is required for LH receptor sensitivity on Leydig cells and for testosterone biosynthesis; deficiency directly impairs testosterone production. Vitamin D receptor signaling supports both LH secretion from the pituitary and testosterone synthesis in the Leydig cell. Magnesium deficiency impairs the free testosterone fraction by affecting SHBG binding. Environmental endocrine disruptors, particularly phthalates, BPA, and persistent organic pollutants, interfere with the steroidogenic enzyme cascade and reduce testicular testosterone output. These nutritional and environmental drivers are often overlooked but are highly actionable.

Conventional vs Functional Medicine Approach

Conventional management of low testosterone is typically binary: either testosterone is above the laboratory minimum and no action is taken, or it falls below the threshold and replacement is initiated without investigating what is driving the deficiency or whether the deficiency is primary or secondary.

Domain	Conventional Medicine	Functional Medicine
Evaluation	Single total testosterone; treat if below 300 ng/dL	Total testosterone, free testosterone, SHBG, LH, FSH, estradiol, prolactin, metabolic panel; full hormonal context
Threshold	Laboratory minimum (300 ng/dL)	Optimal function range (600 to 900 ng/dL total T; free T in upper quartile)
Root cause	Rarely investigated; replacement initiated regardless of mechanism	Primary vs secondary distinguished; specific drivers identified before treatment decision
Treatment options	Testosterone replacement therapy	TRT when indicated; clomiphene or hCG for secondary hypogonadism preserving fertility; root cause correction first when reversible drivers are present
Monitoring	Total testosterone and PSA	Free testosterone, estradiol, hematocrit, PSA, SHBG, metabolic markers, symptom assessment

Key Labs to Evaluate

A complete testosterone evaluation requires a panel that characterizes both the hormonal status and the metabolic context driving it. A single total testosterone drawn at a random time of day without any additional hormonal markers is insufficient for clinical decision-making.

Core Androgen Panel

Pituitary and Upstream Hormones

Metabolic and Safety Panel

How to Interpret These Labs Together

Testosterone evaluation is always a pattern, not a single number. The combination of total testosterone, free testosterone, LH, and SHBG tells a fundamentally different clinical story than any one value in isolation.

Pattern	What It Means
Low total T, low LH, elevated prolactin	Hyperprolactinemia suppressing the HPG axis. Requires pituitary MRI before TRT is initiated. Cabergoline is often the correct first-line treatment.
Low total T, low LH, normal prolactin, history of anabolic steroid use	HPG axis suppression from exogenous androgen history. May recover with time; clomiphene or hCG can accelerate axis recovery.
Low total T, high LH, high FSH	Primary testicular failure. TRT is indicated. Fertility requires specialist evaluation for TESE.
Low-normal total T, high SHBG, symptomatic patient	Functionally deficient free testosterone despite borderline total T. SHBG-driven bioavailability problem. Interventions that lower SHBG or TRT at lower total T threshold are warranted.
Low total T, low LH, insulin resistance, obesity, no other cause	Metabolic hypogonadism. Most reversible pattern. Weight loss and insulin sensitization often partially restore testosterone without TRT.

Common Patterns Seen in Patients

• The "borderline normal" patient who is clearly symptomatic: Total testosterone 340 ng/dL. Told by his primary care physician that his levels are "a little low but within range." He has been experiencing fatigue, difficulty maintaining muscle despite training four days per week, declining libido, and a low-grade depression that has not responded to antidepressants. Free testosterone is below the 25th percentile. SHBG is elevated. This patient is functionally deficient and is being undertreated by a system that treats a threshold rather than a physiology.
• The metabolic hypogonadism pattern: A 44-year-old with a BMI of 32, a waist circumference of 42 inches, a HOMA-IR of 2.9, and a total testosterone of 285 ng/dL. LH is low-normal at 2.1 mIU/mL. This is metabolic secondary hypogonadism driven by visceral fat aromatase and insulin-mediated Leydig cell suppression. Addressing the insulin resistance and reducing visceral adiposity is the highest-leverage intervention and may restore testosterone sufficiently that TRT is not required.
• The post-anabolic patient: A man in his mid-30s who used testosterone or anabolic steroids for several years and has discontinued, now presenting with fatigue, low libido, and a total testosterone of 190 ng/dL with an LH of 0.8 mIU/mL. His HPG axis is suppressed from the exogenous androgen history. Clomiphene or hCG, timed appropriately, can stimulate axis recovery. TRT initiated at this stage would permanently suppress the remaining endogenous production.
• The high-SHBG patient with adequate total T: A lean, aerobically active man in his 50s with a total testosterone of 620 ng/dL who presents with low libido, fatigue, and reduced muscle response to training. SHBG is 78 nmol/L. Free testosterone is 6.2 pg/mL, well below the functional optimal. His total testosterone conceals a functionally deficient free testosterone fraction. Interventions targeting SHBG reduction (addressing thyroid function, reducing aerobic overtraining, moderate dietary fat optimization) or TRT at a threshold calibrated to free rather than total testosterone are the appropriate response.

Treatment and Optimization Strategy

Nutrition and Lifestyle

Before initiating TRT, addressing modifiable lifestyle drivers frequently produces meaningful testosterone improvement and in some patients eliminates the need for exogenous therapy. Resistance training is the most potent non-pharmaceutical testosterone stimulus available: compound movements (squat, deadlift, press) at moderate-to-high intensity with adequate training volume produce acute and chronic testosterone elevation. Reducing visceral adiposity through carbohydrate reduction, time-restricted eating, and sustainable caloric deficit reduces aromatase activity and improves the testosterone-to-estradiol ratio. Sleep optimization is non-negotiable: testosterone is primarily secreted during slow-wave sleep, and chronic restriction below seven hours measurably suppresses morning testosterone levels. Reducing psychological and physiological stress lowers the cortisol burden that suppresses hypothalamic GnRH pulsatility.

Targeted Supplements

What Most Doctors Miss

• Free testosterone is not routinely measured: Total testosterone without SHBG and free testosterone provides an incomplete and frequently misleading picture of androgen status. A man with high SHBG can be functionally deficient at a total testosterone that appears adequate, and a man with low SHBG can have adequate free testosterone at a total testosterone that appears low. The number that matters clinically is the free testosterone, and it is the number most commonly not ordered.
• LH is not measured before initiating TRT: Starting testosterone replacement without knowing whether LH is low (secondary hypogonadism, potentially reversible) or high (primary failure, requiring replacement) means treating without a diagnosis. It also means missing hyperprolactinemia, which requires its own specific treatment, and initiating TRT in a man whose axis could recover with clomiphene, permanently eliminating that option.
• Prolactin is not part of the standard workup: Hyperprolactinemia from a pituitary prolactinoma is a fully reversible cause of secondary hypogonadism that responds to cabergoline, often normalizing testosterone without any testosterone therapy. It is reliably missed when prolactin is not measured as part of the initial evaluation.
• Insulin resistance as the primary driver is not addressed: The most common reversible cause of low testosterone in men is metabolic hypogonadism driven by insulin resistance and visceral adiposity. Initiating TRT in this patient without addressing the metabolic driver means treating a consequence rather than a cause. TRT will improve symptoms but the underlying metabolic dysfunction continues to worsen, and stopping therapy will return the patient to deficiency because the root cause was never addressed.
• Estradiol management during TRT is ignored: Testosterone aromatizes to estradiol, and the degree of aromatization varies significantly between patients depending on body fat, aromatase enzyme activity, and delivery method. Men on TRT with estradiol above 40 to 50 pg/mL frequently experience water retention, mood changes, reduced libido, and gynecomastia that are attributed to testosterone itself rather than to excessive estrogen conversion. Monitoring and managing estradiol is as important as monitoring testosterone during optimization.

When to Seek Medical Care

Low testosterone warrants direct clinical evaluation when symptoms from multiple domains above are present, particularly when they are progressive, inconsistent with life circumstances, or have not responded to lifestyle intervention. Any man over 35 with persistent fatigue, declining body composition, reduced libido, erectile dysfunction, mood changes, or cognitive symptoms should have a complete androgen panel as part of the evaluation rather than attributing these symptoms to aging alone.

Specific situations requiring prompt evaluation: erectile dysfunction in a man under 50 (often the earliest sign of endothelial dysfunction and metabolic disease); infertility or desire for future fertility before any hormonal intervention is initiated; and any symptoms of low testosterone combined with a history of anabolic steroid use, where the HPG axis suppression may require specialized management.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Low Testosterone

Related Conditions

Related Symptoms